Smoking Promotes Subclinical Atherosclerosis in Apparently Healthy Men

Shoji, Shuichi; Nishida, Makoto; Ishii, Kouki; Moriyama, Toshiki; Komuro, Issei; Yamauchi–Takihara, Keiko

doi:10.1253/circj.cj-11-1506

Cited by 21 publications

(13 citation statements)

References 37 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,32 Inflammatory response may be involved in the progression of IMT in male smokers. 19 In the current study, a significant increase in the serum IL-6 level was observed even in female smokers. Therefore, inflammatory response may be also involved in the progression of IMT in female smokers.…”

Section: Laboratory Measurementssupporting

confidence: 50%

“…19 Now, we found prominent progression of subclinical atherosclerosis also in female smokers, according to carotid IMT evaluation. Other risk factors, excluding age, did not significantly correlate with the progression of IMT (data not shown).…”

Section: Laboratory Measurementsmentioning

confidence: 62%

“…19 Changes in the IMT (delta [D] maximum IMT and D mean IMT) during 1 year were measured for 69 women who visited annually for medical checkup (31 smokers, 38 neversmokers).…”

Section: Evaluation Of Carotid Atherosclerosismentioning

confidence: 99%

See 2 more Smart Citations

Smoking Associates With Visceral Fat Accumulation Especially in Women

Nakanishi

Nishida

Ohama

et al. 2014

Circ J

Self Cite

View full text Add to dashboard Cite

Section: Laboratory Measurementssupporting

confidence: 50%

Section: Laboratory Measurementsmentioning

confidence: 62%

See 1 more Smart Citation

Smoking Associates With Visceral Fat Accumulation Especially in Women

Nakanishi

Nishida

Ohama

et al. 2014

Circ J

Self Cite

View full text Add to dashboard Cite

“…Variation of systolic and diastolic blood pressure and heart rate in a sub-sample over time 1 . However, a significant positive correlation was observed between dAix@75 and HR, and dAix@75 after smoking and HR pre-post smoking, indicating that cardiac frequency is enhanced by increasing vessel stiffness.…”

Section: Tablementioning

confidence: 99%

Acute cigarette smoking impairs microvascular function in young moderate smokers: A potential model for studying vasoactive properties of food bioactives

et al. 2014

View full text Add to dashboard Cite

“…11 Smoking has been advocated as a major risk factor for coronary artery disease. 12 It has been reported that smoking is associated with a 2-4-fold increased risk of coronary events including sudden cardiac death, and worsens outcomes after PCI or coronary bypass surgery. 13,14 Therefore, smoking is a major concern for clinicians treating patients with coronary artery disease.…”

Section: Platelet Function Testmentioning

confidence: 99%

Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation

Kim

Suh

Lee

et al. 2014

Circ J

View full text Add to dashboard Cite

Background: The present study investigated whether cilostazol can eliminate adverse smoking outcome after percutaneous coronary intervention (PCI). Methods and Results:A total of 914 patients with successful drug-eluting stent (DES) implantation were randomly assigned to dual antiplatelet therapy (DAT; aspirin and clopidogrel, n=457) or to triple antiplatelet therapy (TAT; DAT with cilostazol, n=457). The effect of smoking on 2-year major adverse cardio/cerebrovascular events (MACCE) in both the TAT and DAT groups was evaluated. Total MACCE were not significantly different between the 2 anti-platelet regimens (9.8% in TAT vs. 11.4% in DAT groups, P=0.45), but the adverse effects of smoking on clinical outcome were different between DAT vs. TAT. Current smokers had a higher prevalence of MACCE than non-smokers in the DAT group (16.7% vs. 9.5%, P=0.04). In the TAT group, however, the adverse effect of smoking was abolished (9.2% vs. 10.1%, P=0.85). Regarding the effects of smoking on the antiplatelet effects of DAT or TAT, post-treatment platelet reactivity (in P2Y12 reaction units; PRU) in current smokers was not significantly lower than that in non-smokers in the DAT group, whereas, in the TAT group, it was significantly lower than that of non-smokers (189±88 vs. 216±89 PRU, P=0.01). Conclusions:Adverse clinical effects of smoking may be eliminated by the addition of cilostazol to DAT after DES implantation. This may be due to the stimulation of cilostazol's antiplatelet effects by smoking. (Circ J 2014; 78: 1420 -1427

show abstract

Smoking Promotes Subclinical Atherosclerosis in Apparently Healthy Men

Cited by 21 publications

References 37 publications

Smoking Associates With Visceral Fat Accumulation Especially in Women

Smoking Associates With Visceral Fat Accumulation Especially in Women

Acute cigarette smoking impairs microvascular function in young moderate smokers: A potential model for studying vasoactive properties of food bioactives

Cilostazol Eliminates Adverse Smoking Outcome in Patients With Drug-Eluting Stent Implantation

Contact Info

Product

Resources

About